Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.
Rao AV, Younis IR, Sand GJ, Spasojevic I, Adams DJ, Decastro CM, Gockerman JP, Peterson BL, Petros WP, Moore JO, Rizzieri DA. Rao AV, et al. Among authors: rizzieri da. Leuk Lymphoma. 2008 Aug;49(8):1523-9. doi: 10.1080/10428190802210700. Leuk Lymphoma. 2008. PMID: 18766965 Clinical Trial.
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.
Shea TC, Beaven AW, Moore DT, Serody JS, Gabriel DA, Chao N, Gockerman JP, Garcia RA, Rizzieri DA. Shea TC, et al. Among authors: rizzieri da. Leuk Lymphoma. 2009 May;50(5):741-8. doi: 10.1080/10428190902853136. Leuk Lymphoma. 2009. PMID: 19358012 Clinical Trial.
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.
Advani AS, Shadman M, Ali-Osman F, Barker A, Rybicki L, Kalaycio M, Sekeres MA, de Castro CM, Diehl LF, Moore JO, Beaven A, Copelan E, Sobecks R, Talea P, Rizzieri DA. Advani AS, et al. Among authors: rizzieri da. Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):473-6. doi: 10.3816/CLML.2010.n.082. Clin Lymphoma Myeloma Leuk. 2010. PMID: 21156465 Clinical Trial.
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
Lanasa MC, Davis PH, Datto M, Li Z, Gockerman JP, Moore JO, DeCastro CM, Friedman DR, Diehl LF, Rehder C, Cook H, Daugherty FJ, Matta KM, Weinberg JB, Rizzieri D. Lanasa MC, et al. Leuk Lymphoma. 2012 Feb;53(2):218-24. doi: 10.3109/10428194.2011.610012. Epub 2011 Sep 23. Leuk Lymphoma. 2012. PMID: 21827374
248 results